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Altered autonomic (ANS) tone in chronic respiratory disease is implicated as a factor
in cardiovascular co-morbidities, yet no studies address its impact on cardiovascular
function in the presence of murine allergic airway (AW) hyperresponsiveness (AHR).
Since antigen (Ag)-induced AHR is used to model allergic asthma (in which ANS
alterations have been reported), we performed a pilot study to assess measurement
feasibility of, as well as the impact of allergic sensitization to ovalbumin (OVA) on, heart
rate variability (HRV) in a murine model. Heart rate (HR), body temperature (TB), and
time- and frequency-domain HRV analyses, a reflection of ANS control, were obtained
in chronically instrumented mice (telemetry) before, during and for 22 h after OVA or
saline aerosolization in sensitized (OVA) or Alum adjuvant control exposed animals. OVA
mice diverged significantly from Alum mice with respect to change in HR during aerosol
challenge (P < 0.001, Two-Way ANOVA; HR max change Ctrl = +80 ± 10bpm vs. OVA
= +1 ± 23bpm, mean ± SEM), and displayed elevated HR during the subsequent dark
cycle (P = 0.006). Sensitization decreased the TB during aerosol challenge (P < 0.001).
Sensitized mice had decreased HRV prior to challenge (SDNN: P = 0.038; Low frequency
(LF) power: P = 0.021; Low/high Frequency (HF) power: P = 0.042), and increased HRV
during Ag challenge (RMSSD: P = 0.047; pNN6: P = 0.039). Sensitized mice displayed
decreased HRV subsequent to OVA challenge, primarily in the dark cycle (RMSSD:
P = 0.018; pNN6: P ≤ 0.001; LF: P ≤ 0.001; HF: P = 0.040; LF/HF: P ≤ 0.001). We
conclude that implanted telemetry technology is an effective method to assess the ANS
impact of allergic sensitization. Preliminary results show mild sensitization is associated
with reduced HRV and a suppression of the acute TB-response to OVA challenge. This
approach to assess altered ANS control in the acute OVA model may also be beneficial in
chronic AHR models.
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INTRODUCTION
Asthma is an inflammatory condition of the airways (AW) char-
acterized by airway hyperresponsiveness (AHR), inflammatory
cell infiltration and reversible bronchoconstriction, which, on a
chronic basis, progresses to AW remodeling (Boulet et al., 1999;
Holgate, 2008; Lougheed et al., 2010). Asthma is often modeled
in animals through allergic induction of AHR, which is charac-
terized by a decrease in the bronchoconstrictive threshold and
Abbreviations: AHR, Airway Hyperresponsiveness; Alum, Alum Adjuvant
Control Group; ANS, Autonomic Nervous System; AW, Airway; BAL,
Bronchoalveolar Lavage; HF, High Frequency Power; HR, Heart Rate; HRV,
Heart Rate Variability; LF, Low Frequency Power; MCh, Methacholine; OVA,
Ovalbumin; PAW, Airway Pressure; pNN6, Percentage of consecutive normal R-R
intervals differing by more than 6ms; RMSSD, Square root of the mean of the
sum of squares of successive differences between normal R-R intervals; RRS, Total
Respiratory Resistance; SDNN, Standard deviation of normal R-R intervals; TI,
Inspiratory Time; TB, Body Temperature; VT, Tidal Volume; WBC, White Blood
Cell.
an increase in the maximal response generated for bronchocon-
strictive stimuli (Boulet et al., 1999; Kumar et al., 2008; Allen
et al., 2009). Patients with asthma show altered heart rate vari-
ability (HRV) profiles (Tokuyama et al., 1985; Lewis et al., 2006).
In general, decreased HRV is associated with decreased cardio-
vascular prognosis (Chattipakorn et al., 2007). Although HRV
analysis has been successfully adopted for use in murine models,
to our knowledge this tool has not been applied to models of AHR
(Thireau et al., 2008). Further, the mechanism(s) responsible for
alterations in HRV and the time-course of their development in
asthma are unknown. We addressed the hypothesis that changes
in autonomic control, particularly HRV, are initiated early in
the development of AHR. We assessed the utility of a chron-
ically instrumented murine model of acute ovalbumin (OVA)
sensitization, in which we investigated the effect of sensitization
and antigen (Ag; i.e., OVA) challenge on the regulation of heart
rate (HR) using time- and frequency-domain HRV analysis of
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ECG, as well as on core body temperature (TB) and activity
between groups.
MATERIALS AND METHODS
All experiments were approved by the Queen’s Animal Care
Committee and performed according to the guidelines of the
Canadian Council of Animal Care.
PROTOCOL
We employed an OVA sensitization model (Walker et al.,
2003; Kumar et al., 2008) in which male C57BL/6 mice
(5 weeks old upon arrival; Charles River Canada) were ran-
domly assigned to either OVA or aluminum hydroxide adju-
vant control (Alum) groups. Mice were surgically implanted
with sterile i.p., radiotelemetry devices (TA 10 ETA-F20; DSI
International, St. Paul, MN) and allowed a 2-weeks recovery
period to reestablish circadian variation [unpublished observa-
tions; (Thireau et al., 2008)]. Body weights prior to OVA inhala-
tional challenge (mean ± SD) were not different between groups;
35.4 ± 2.0 g and 33.4 ± 3.8 g for OVA and Alum groups, respec-
tively (P > 0.05). Animals were housed in a 12-h light/dark cycle
(08:00–20:00 h light, 20:00–08:00 h dark) environment with an
ambient temperature of 22◦C, and ad libitum access to food and
water.
Sensitization, OVA challenge and data collections were stag-
gered among the mice to accommodate in vivo physiologic mea-
surements of AHR. The protocol consisted of 3 weeks of primary
sensitization (or Alum control) followed by secondary sensitiza-
tion and exposure to aerosolized OVA solution or sterile saline
(Figure 1).
PRIMARY SENSITIZATION
Primary Sensitization consisted of i.p., injections (0.2ml) of OVA
suspended in aluminum hydroxide adjuvant (OVA group: 50µl
of 1mg/ml A5503 Albumin Grade V + 80µl of 13mg/ml A8222
Aluminum Hydroxide Gel “Alhydrogel,” both Sigma-Alrich Inc.,
St. Louis, MO, + 870µl sterile saline) or aluminum hydrox-
ide adjuvant in saline (Alum group: 77µl of 13mg/ml A8222
Aluminum Hydroxide Gel “Alhydrogel,” Sigma-Alrich Inc., St.
Louis, MO, + 923µl sterile saline) administered once weekly for
3 weeks. Injections were given at consistent times of day and by
the same individual to minimize intra-procedural variability.
SECONDARY AEROSOL CHALLENGE
Mice were exposed to aerosolized challenges (60min) on 3 con-
secutive days at approximately the same time each day (within
40min). Solutions (1% weight/volume A5503 Albumin Grade
V OVA in sterile saline and sterile saline for OVA and Alum
groups, respectively,) were aerosolized by an ultrasonic nebu-
lizer (Ultrasonic 2000 by Nouvag Dental andMedical Equipment;
Goldach, Switzerland; particle size = 3.8–4.0µm, chamber air-
flow = 700ml/min). Aerosolized Ag challenges were performed
in sealed 1.6 L Plexiglas chambers.
On the third aerosol exposure day (day 23 of protocol), teleme-
try data for ECG waveform, TB and activity data were acquired
during acclimation to the exposure-chamber (60min prior to
OVA/saline challenge), aerosolization (60min of challenge) and
FIGURE 1 | Sensitization and experimental protocols. Primary
(i.p., injection) and secondary (aerosol) sensitizations occurred as indicated
in the upper panel; expanded view comprises the third aerosol challenge
(OVA or saline) on day 23. HR, TB, and activity data were collected on day
23 as indicated for 1 h prior to aerosol (light gray arrow), 1 h during aerosol
(gray arrow), and 22 h post-challenge (black arrow). Subsequently, MCh
challenge (RRS) was performed, and blood and BAL samples collected for
analysis of inflammatory cells.
for a subsequent 22 h post- challenge. Activity represents the rel-
ative locomotive activity of each animal, measured on the basis
of the strength of the transmitted signal (telemetry device) to the
Data Exchange Matrix; distance and speed of movement (“move-
ment” includes orientation and distance) are considered in the
calculation of activity units.
Data were sampled for 3min on a 10min interval schedule
(ECG at 2k samples/s; TB at 250 samples/s and activity at 64 sam-
ples/s; Dataquest ART Software, DSI International; St. Paul, MN).
Temporally-synchronized video was monitored to provide visual
surveillance of each mouse during the hour of aerosol challenge
(15 frames/s).
In vivo AIRWAY CHALLENGE
Following the telemetry protocol mice were anesthetized (sodium
pentobarbital i.p., 60mg/kg; dilution = 30mg/ml), a tracheal
cannula inserted and mechanical ventilation initiated (peak
tracheal pressure: circa 7.5 cm H2O, respiratory frequency:
120 breaths/min; MOD.RV5Ventilator, Voltek Enterprises Inc.,
Toronto, ON). This level of ventilation abolished respiratory
efforts prior to administration of pancuronium bromide. The
right jugular vein was catheterized to allow for intra-venous
administration of supplemental anesthetic, pancuronium bro-
mide (0.25mg/kg) and methacholine (MCh). Arterial blood
pressure was measured via a 1F Mikro-Tip Catheter Pressure
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Transducer (Millar: Sensors, Systems, Solutions; Houston, TX)
inserted into the aortic arch via the left carotid artery.
Logarithmic dose-response curves for MCh were generated
for all mice (dosage = 3µg/kg, 10µg/kg, 30µg/kg, 100µg/kg).
Doses were administered at 15min intervals, and were preceded
by hyperinflation (two breaths) and a 2-min post-inflation period
to control volume history. Following 30 s of baseline record-
ing, MCh was injected via the jugular catheter, and responses
over 100 s were recorded (ECG, blood pressure, transrespiratory
system pressure, tidal volume [VT], and flow). Total respira-
tory resistance (RRS) was calculated on a breath-by-breath basis
according to the method of Ewart et al. (1995) as measured
using a ventilator technique described by Volgyesi et al. (2000).
All signals were acquired digitally (SPIKE2 software, Cambridge
Electronic Design, Cambridge, UK), and RRS was defined as
the ratio of the resistive AW pressure (peak PAW–plateau PAW;
cm H2O) to flow, defined by VT over inspiratory time (VT/TI;
ml/s). Maximum RRS values for each dose of MCh were
reported.
INFLAMMATORY CELL ANALYSIS
Bronchioalveolar lavage (BAL) samples for total white blood
cell (WBC) count were centrifuged (5min at 12,000 RPM),
the supernatant removed and red blood cell lysis achieved
through resuspension of the pellet in 1ml lysis solution buffer
(Tris/Amm. Cl). The solution was re-spun and the supernatant
discarded. Following resuspension of the pellet in 1ml sterile,
buffered saline, total cell count was taken using a hemocytometer
(10µl fluid loaded). Data were reported as cells/ml.
BAL samples for differential WBC analysis (100µl resus-
pended BAL; above) were loaded onto assembled cytospin cas-
settes along with 50µl debris-free fetal calf serum. Samples
were centrifuged (3min at 800 RPM; Shandon Cytospin, Thermo
Scientific, Kalamazoo,MI) and cells were allowed to dry ≥ 15min
before staining using the Protocol Hema3 Staining Kit (Fisher
Scientific Co., Kalamazoo, MI). Differential counts (results
reported in percent of total WBC population; minimum 200 cells
total) were obtained for macrophages, neutrophils, lymphocytes,
eosinophils, and AW epithelial cells.
Blood samples for total WBC count (20µl) were mixed with
190µl lysis solution buffer (Tris/Amm.Cl) and allowed to react
for 10min. Cells were counted through use of a hemocytometer
(10µl loaded) and results reported as cells/µl. Standard smears
of the differential WBC count samples were made and allowed to
dry on glass slides using 10µl of well-mixed blood. Slides were
stained using the Protocol HEMA3 kit and 100 circulating WBCs
were differentiated, with results being reported as percentage of
total WBCs.
STATISTICAL ANALYSIS
Statistical analyses were performed using SigmaStat 3.0 (Systat
Software Inc., San Jose, CA). Parametric statistical analyses con-
sisted of paired t-tests or One-Way and Two-Way analysis of vari-
ance (ANOVA) as indicated. If the assumptions for parametric
tests were notmet, ranked data were used in non-parametric anal-
yses. Post-hoc tests (Holm-Sidak) were performed as appropriate.
A significant difference was defined as P < 0.05.
HRV ANALYSIS
Time- and frequency-domain HRV analyses were based on the
standards developed by Thireau et al. for murinemodels (Thireau
et al., 2008). Raw ECG data were analyzed manually for peak
detection of R waves in order to obtain R-R, or inter-beat,
intervals (IBI), which were exported into Excel for time domain
analysis. Frequency domain analyses were performed offline using
Matlab (MATLAB/R2010a; The MathWorks Inc., Natick, MA).
Manual selection ensured that only true sinus beats were included
in analysis and circumvented analytical issues associated with
automated software (Torbey et al., 2012). This procedure removed
the need to exclude beats outside two standard deviations of the
mean, a filteringmethod generally employed to exclude non-sinus
events (Thireau et al., 2008).
Time domain analysis was performed for all 3-min segments
by calculating standard deviation of all normal R-R intervals
(SDNN), square root of the mean of the sum of squares of
successive differences between normal R-R intervals (RMSSD),
and percentage of consecutive R-R intervals differing by more
than 6ms(pNN6) (Thireau et al., 2008). Comparisons were made
between groups for all 3-min segments during acclimatization
and aerosolization, and on an hourly basis for post-aerosolization
data spanning 3–24 h of the protocol (each hour consisted of
the mean of the six data points; i.e., one 3-min segment per
10min).
In order to gain insight into the respective contributions
of the sympathetic and parasympathetic nervous systems to
heart rhythm, frequency domain HRV analysis was executed
by fast Fourier transformation (FFT). R-R interval series were
re-sampled to a 20Hz inter-beat time series, mean-detrended,
and Hamming windowed. The squared magnitudes of the dis-
crete Fourier transform of the segments were averaged to form
power spectral density. The frequency domain HRV parameters
computed for all 3-min segments were: low frequency power
(LF; 0.15–1.5Hz), reflecting sympathetic activity; high frequency
power (HF; 1.5–5Hz), reflecting parasympathetic activity; and
the LF/HF power ratio (Thireau et al., 2008). Although an
LF band of 0.4–1.5Hz has been recommended by numerous
researchers (Wickman et al., 1998; Gehrmann et al., 2000; Pelat
et al., 2003; Williams et al., 2003; Duan et al., 2007), we selected
0.15–1.5Hz, as recommended formurinemodels by Thireau et al.
(2008).
We performed further experiments on an additional group of
mice given identical sensitization and exposure protocols to those
outlined above. In these mice, the bronchoconstrictive effect of
bolus right heart injection of 50mg/kg OVA, as well as the bron-
choconstrictive response to increasing doses of inhaled MCh, was
measured.
RESULTS
OVA sensitization resulted in AHR to MCh in the OVA exposed
group compared to the Alum controls (Figure 2, top panel;
P < 0.05). There was a tendency for changes in both the net WBC
content of systemic blood and BAL consistent with pulmonary
inflammation in OVA-sensitized mice; however, this did not reach
statistical significance. Differential WBC analysis of the BAL fluid
is consistent with a predominantly eosinophilic inflammation in
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FIGURE 2 | Effect of sensitization on AHR and pulmonary WBC profile.
Top panel: OVA sensitization resulted in AHR, measured as an increased
percent change in RRS in response to MCh (t-test; P < 0.05). Bottom
panels: Effect of OVA sensitization on systemic blood and BAL white blood
cell count and BAL differential WBC profile. Non-significant trends toward
increased localized pulmonary inflammation, as reflected by modest
eosinophilia (Eos) in the OVA group, were observed in analyses of net WBC
(bottom left) and white blood cell population breakdown (right panel;
percent of population).
OVA-sensitized mice compared with Alum controls (Figure 2,
bottom right panel).
Systemic (right heart) injections of 50mg/kg OVA in
a separate group of sensitized mice caused a 62 ± 14%
(mean ± SEM) increase in RRS from baseline (1.3 ± 0.4 cm
H2O/mL/s; mean ± SEM), which was consistent with the MCh
response to 3–10µg/kg in the same group (RRS increases of
29 ± 7 and 89 ± 20%, respectively).
PHYSIOLOGIC IMPACT OF OVA SENSITIZATION
Modest changes in HR, TB and activity observed within each
group during challenge were not statistically different from pre-
aerosol baseline. However, analyses of HR, TB and activity were
different between groups and revealed that OVA sensitization
attenuated the trend toward increased HR and TB relative to base-
line that was observed in the Alum group (Figure 3, P ≤ 0.001;
maximum positive change in HR for Alum = 80 ± 10 bpm, for
OVA= 1± 23 bpm,mean± SEM). There was no difference in the
activity profiles between the two groups during aerosol challenge
(P > 0.05).
HRV analysis in both time- and frequency-domains (SDNN,
RMSSD, pNN6, LF, HF, and LF/HF) was analyzed separately
for the acclimation and aerosol challenge (each 1 h). During
FIGURE 3 | Change in HR (top panel), TB (middle panel), and activity
(bottom panel) during aerosol challenge. The baseline control values
(CON) were calculated based on the means of HR, TB, and activity for the
40min directly preceding Ag challenge. OVA-sensitized mice displayed a
decreased HR and TB profile compared with Alum control mice (both
P ≤ 0.001 via Two-Way ANOVA, activity: NSD; Holm-Sidak post-hoc
analyses: ∗P < 0.05; ∗∗P < 0.01).
the acclimation control period, three of the HRV variables were
significantly decreased in the OVA-sensitized mice compared with
Alum controls; specifically, SDNN (P < 0.05), LF (P < 0.025),
and LF/HF (P < 0.05) (Figure 4). The remaining HRV vari-
ables were not significantly different, although they tended to be
reduced in comparison with Alum control mice. During aerosol
challenge, RMSSD (P < 0.05) and pNN6 (P < 0.05) were signif-
icantly elevated in OVA-sensitized mice (Figure 4) compared to
Alum controls, whereas SDNN, LF, HF, and LF/HF did not vary
significantly between groups (P > 0.05).
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FIGURE 4 | Heart rate variability prior to and during aerosol challenge.
The acclimation control period (0–60min) and aerosol challenge (70–130min,
to accommodate sampling) were independently analyzed by Two-Way
ANOVA and Holm-Sidak post-hoc analyses; ∗P < 0.05. During acclimation,
OVA-sensitized mice displayed decreased SDNN (P < 0.05), LF (P < 0.025),
and LF/HF (P < 0.05) compared with Alum control mice. During aerosolized
Ag challenge, RMMSD (P < 0.05) and pNN6 (P < 0.05) were significantly
increased in OVA-sensitized mice compared to the Alum controls.
Analysis of 3–24 h post-aerosol challenge revealed that HR
and activity were elevated in OVA-sensitized mice compared
with Alum mice (P ≤ 0.001 and P = 0.008, respectively; data
not shown). Separate analysis of the light/dark cycle follow-
ing sensitization (Figure 5) revealed that OVA sensitization
was associated with an elevation in HR relative to Alum
controls during the dark cycle (P < 0.01). There were no
significant differences in TB or activity between groups for
either of the independently analyzed light or dark cycles
(P > 0.05).
Six HRV parameters were analyzed for both the light and
dark cycles (Figure 6). During the light cycle, LF was decreased
in OVA-sensitized mice (P = 0.036), whereas five of the six
HRV parameters were decreased during the dark cycle for
OVA-sensitized mice (RMSSD, P = 0.018; pNN6, P ≤ 0.001; LF,
P ≤ 0.001; HF, P = 0.040 and LF/HF, P ≤ 0.001).
DISCUSSION
The use of telemetered biological signals from chronically
instrumented mice, coupled with the translation ofHRVmethod-
ology to murine models (Thireau et al., 2008), provides a pow-
erful experimental model to assess autonomic control in vivo.
A primary outcome of our study was the demonstration of the
viability of this approach, which incorporates abdominal implan-
tation of the telemetry transmitter, to characterize the integrative
biology/phenotype of the OVA allergen sensitization model. To
our knowledge, the present study is the first to examine the
murine integrative phenotype associated with the OVA model, as
reflected by HR, TB and HRV measurements, which are linked to
autonomic nervous system (ANS) control (Thayer et al., 2011).
We found that OVA sensitization was associated with altered
control/baseline HRV prior to the aerosol challenge, as reflected
by decreased SDNN, LF, and LF/HF. This suggests that early
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FIGURE 5 | HR (top panel), TB (middle panel), and activity
(bottom panel) during the light and dark cycles immediately following
Ag challenge. HR was increased in OVA-sensitized mice during the dark
cycle (13–22 h) following Ag challenge (P < 0.01; Two-Way ANOVA with
Holm-Sidak post-hoc analyses; ∗P < 0.05).
sensitization, prior to airway remodeling, may already exert sub-
tle influences on autonomic control. Control of both HR and
TB during aerosol challenge, as well as HR in the circadian
dark cycle subsequent to aerosol challenge, was altered in OVA-
sensitized mice relative to the alum controls. OVA sensitization
was associated with altered HRV (increased RMSSD and pNN6)
during aerosolization challenge, as well as during the dark phase
subsequent to aerosol challenge (decreased RMSSD, pNN6, LF,
HF, and LF/HF compared to controls). Thus, our findings sug-
gest that subtle changes in autonomic control are initiated early
in the development of Ag sensitization associated with airway
hyperresponsiveness (AHR).
METHODOLOGICAL CONSIDERATIONS
The use of a validated method to measure an enhanced RRS
response to MCh (Volgyesi et al., 2000; Ewart et al., 2001;
Walker et al., in this issue) indicated the presence of AHR
due to the OVA protocol [Figure 2, top panel; (Kumar et al.,
2008)]. Since our model required inhalation of OVA aerosol,
it is possible that the changes we observed in HRV and other
variables during and/or after the third and final OVA expo-
sure were a consequence of a bronchoconstrictor response to
inhaled antigen, rather than overall changes in autonomic control
associated with early allergic sensitization/AHR. Several obser-
vations suggest this may be unlikely in conscious mice. First,
OVA-sensitized mice displayed changes in baseline HRV that
were present prior to the final OVA exposure and the onset of
presumed changes in bronchomotor tone. Based on the cur-
rent literature, it is not clear if, when, or to what degree OVA
inhalation causes bronchoconstriction in the murine model. For
example, AHR to contractile agonists has been demonstrated to
occur prior to the presence of a bronchoconstrictor response
to inhaled OVA in sensitized mice (Neuhaus-Steinmetz et al.,
2000). Additionally, bronchoconstriction to inhaled OVA has
been shown to require multiple exposures (Zhang et al., 1997;
Neuhaus-Steinmetz et al., 2000), with the magnitude of bron-
choconstriction increasing with additional exposures (Neuhaus-
Steinmetz et al., 2000). Secondly, putative methods to measure
bronchoconstriction non-invasively in conscious animals, such
as enhanced pause (Penh) or peak expiratory flow measure-
ments, do not provide accurate or robust measurements of
bronchoconstriction (see Walker et al., this volume, for review).
As a result, data do not appear to be available to demonstrate
that the third OVA exposure caused acute bronchoconstriction.
This is an important unanswered question in the literature on
murine models, which is further complicated by the wide array
of variable murine OVA models documented in the literature
(Holgate, 1999; Pabst, 2002; Kips et al., 2003; Epstein, 2004;
Changh and Mitzner, 2007; Zosky and Sly, 2007; Kumar et al.,
2008; Nials and Uddin, 2008; Zosky et al., 2008; Allen et al.,
2009).
In order to gain some insight into bronchoconstrictor sen-
sitivity to antigen, we performed additional studies on sen-
sitized animals in which the RRS response to vascular (right
heart injection) delivery of OVA (50mg/kg) was measured in
anaesthetized, mechanically ventilated mice. Single high dose
OVA increased Rrs comparable to that seen for low dose MCh
(see section “Results”). This exposure is likely to be far greater
than the dosage of OVA delivered through inhalation, where
upper airway impaction, large airway branch-point deposition
and the presence of a robust airway epithelial barrier (Hogg,
1982; Turi et al., 2011) all conspire to reduce the dosage of
agonist delivered to submucosal airway smooth muscle sites.
Thus, it is possible that the final inhaled OVA exposure may
not have significantly altered RRS or induced bronchoconstric-
tion. If so, then changes in variables such as HR, HRV, TB
and activity, during and after exposure (i.e., subsequent 22 h)
may be a reflection of the development of sensitivity in the
OVA-model, and the underlying link between inflammation
and the autonomic nervous system. Unfortunately, our data
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FIGURE 6 | The effect of OVA sensitization on HRV during the
light and dark cycles immediately following aerosol challenge.
During the light cycle, OVA sensitization resulted in decreased LF
relative to Alum controls (3–10 h; P < 0.05). During the dark cycle,
OVA sensitization resulted in decreased RMSSD (P < 0.025),
pNN6 (P ≤ 0.001), LF (P ≤ 0.001), HF (P < 0.05), and LF/HF
(P ≤ 0.001; Two-Way ANOVA with Holm-Sidak post-hoc analyses;
∗P < 0.05).
do not allow us to address the above questions definitively;
however, they identify an important question for subsequent
investigation.
EARLY SENSITIZATION AND PHYSIOLOGIC OUTCOMES
The functional change in AW responsiveness is accompa-
nied, and arguably caused, by inflammatory changes, such as
the localized infiltration of eosinophils into the AWs (Jacoby
et al., 2001). We observed a trend (not statistically differ-
ent) with respect to inflammatory mediators within the WBC
content and populations of systemic blood and BAL fluid
of OVA-sensitized mice, which is consistent with pulmonary
inflammation, eosinophilia and the early nature of the sensitiza-
tion. The statistical outcome may have also been influenced by
group size.
Our acute model of OVA-induced AHR likely recreated the
earliest functional stage of disease, prior to the remodeling rou-
tinely described in chronic asthma (Joos et al., 2000; Holgate,
2008; Allen et al., 2009). Although AW function was directly
assessed 22 h subsequent to Ag challenge, as mentioned above
we did not directly assess the presence or absence of early-
and/or late-phase reactions (Boulet et al., 1999; Holgate, 2008).
However, HRV analysis, in concert with analyses of HR, TB and
activity, suggests the impact of Ag exposure resulted in an altered
overall autonomic profile for OVA-sensitized mice. Indeed, OVA-
sensitized mice displayed a decreased HR and TB profile during
the Ag challenge compared to the Alum group (Figure 5). These
differences were not activity related since the profiles were the
same between groups. The changes in HR persisted after Ag chal-
lenge, with OVA-sensitized mice displaying increased HR during
the dark cycle, over 10 h following the aerosolization exposure.
HRV ANALYSES
Quantifiable, integrative measures of end-organ responsiveness,
changes in HR (gross autonomic balance) and HRV have been
suggested to be robust indices of cardiac health in human subjects
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(Zwiener et al., 2002; Sandercock and Brodie, 2006; Chattipakorn
et al., 2007; Thireau et al., 2008). We performed the two pre-
dominant types of HRV analyses: time-domain, which reflects the
statistical analysis of IBIs in parameters such as SDNN, RMSSD,
and pNN6, and frequency-domain, based on the spectral analy-
sis of IBIs reflected by LF, HF, LF/HF (Figures 4, 6) (E.S.C and
N.A.S.P.E. Task Force, 1996; Thireau et al., 2008). In humans,
decreases in HRV are associated with worse prognoses, and HRV
is an independent predictor of cardiac morbidity and mortal-
ity, and a useful tool for non-invasively measuring changes in
sinoatrial (SA) ANS activity in health and disease (Tarkiainen
et al., 2005; Parati et al., 2006; Sandercock and Brodie, 2006;
Chattipakorn et al., 2007; Thireau et al., 2008). We adopted the
guidelines developed by Thireau et al. for HRV analysis with-
out correction for the potential impact of respiration on HRV
(Thireau et al., 2008). More recently, it has been suggested that
the presence of bi-directional cross-talk between the cardiovascu-
lar and respiratory systems, or cardiorespiratory coupling, makes
correction for respiration less convincing in the examination of
HRV (Tzeng et al., 2003; Thayer et al., 2011). Nevertheless, addi-
tional studies are required to assess the potential changes in
pattern of breathing and lung volume, which may have occurred
during OVA exposure.
HRV indices may represent specific components of the ANS;
some investigators believe that time-domain HRV parameters can
be ascribed to net autonomic activity (SDNN), short-term HRV
(RMSSD), and PSNS activity (pNN6, or its human equivalent
pNN50) (Thireau et al., 2008; Tascilar et al., 2009). Others have
reported both RMSSD and pNN6 to primarily reflect short-term
HR modulation, or PSNS activity, with SDNN reflecting the bal-
ance between the PSNS and SNS, or a combination of short-term
(e.g., respiratory) and long-term (e.g., circadian) factors (Stein
et al., 1994). Similarly, while HF HRV fluctuations are generally
considered to be a reasonable approximation of PSNS activity, LF
HRVfluctuations have been reported to reflect both SNS as well as
a combination of SNS and PSNS activity (Pomeranz et al., 1985;
Parati et al., 2006). Despite suggestions that HRV reflects inte-
grated ANS activity at the level of the SA node, caution should be
exercised in ascribing a link between specific components of the
ANS and individual HRV parameters variables (Parati et al., 2006;
Taylor and Studinger, 2006a,b). Interestingly, studies investigating
HRV in humans have shown PSNS activity to be inversely related
to systemic inflammation, as assessed by C-reactive protein lev-
els (Thayer and Fischer, 2009). This association was stronger in
females than in males. The present study used only male mice,
and it remains to be seen if such associations are present between
sexes for mice.
CONTROL AND AEROSOL EXPOSURE
We investigated HRV prior to, during, and subsequent to aerosol
challenge. During the hour prior to aerosol challenge (acclima-
tion), three indices of HRV (SDNN, LF, LF/HF; all P < 0.05) were
decreased in OVA-sensitized mice. These results suggest that there
is a small, but significant alteration in ANS activity prior to Ag
challenge, presumably due to the effects of sensitization alone.
This decrease in activity may be linked to the sympathetic nervous
system, as LF as well as LF/HF and SDNN were decreased in OVA
mice, while RMSSD, pNN6, and HF were unchanged between
groups.
During Ag challenge, RMSSD and pNN6 were increased
(P < 0.05) in OVA mice, which is consistent with the time
domain HRV results of Tascilar and colleagues for symptomatic
pediatric patients with allergic rhinitis (Tascilar et al., 2009).
We speculate the increase in RMSSD and pNN6 may be linked
to an increase in pulmonary cholinergic tone, as supported by
AHR during the MCh challenge. Reports of heightened cardiac
vagal reactivity, despite insignificant alteration in basal vagal tone,
have been reported in asthmatic patients (Lewis et al., 2006).
Additionally, early studies reported increased indices of HRV in
pediatric patients with asthma (Tokuyama et al., 1985). Increases
in PSNS activity may reflect the increase in cholinergic bron-
choconstrictive activity during an acute asthma exacerbation.
Whether pathogenic changes in bronchial vagal tone can indepen-
dently translate into changes in cardiac vagal tone is somewhat
controversial, with evidence in support either enhanced or unal-
tered cardiac vagal activity in cases of high bronchial vagal activity
(Lewis et al., 2006). Our murine model differed from Tascilar’s
human population in regards to its frequency domain responses;
no differences in frequency domain parameters were observed in
the present study, whereas increased HF and decreased LF/HF
were reported in the above-mentioned study (Tascilar et al.,
2009). It remains to be seen whether the parallelism observed
in the time domain results is maintained in comparisons with
antigen exposures for human asthma or AHR.
HR, TB, and activity were further investigated during the light
and dark cycles following aerosol challenge, with OVA-sensitized
mice displaying increased HR compared with Alum mice during
the dark cycle 13–22 h after protocol initiation, over 10 h after
aerosolization challenge. This further supports the concept of
altered ANS control linked to sensitization, not exclusively during
acute Ag exposure, as sensitized mice displayed persistent changes
from Alum controls well after the aerosolization period. Analysis
of HRV parameters in the light/dark cycles subsequent to the
aerosol challenge period revealed that sensitized mice displayed
decreased HRV in all, but one (SDNN) of the HRV indices dur-
ing the dark cycle (during the light cycle only LF was decreased
in OVA-sensitized mice). These results are consistent with stud-
ies demonstrating a correlation between absolute HR and asthma
severity, where HR increases compared to controls as asthma
severity increases (Kazuma et al., 1997). Further, our results are
consistent with observations of decreased HRV during high abso-
lute HR (Tascilar et al., 2009) There were no differences in activity,
TB or light-cycle HR. As HRV has been shown to be influenced
by physical activity level (e.g., moderate-to-vigorous activity may
help normalize HRV profiles in asthmatic subjects) the lack of
difference in activity profiles of the two groups in the present
study suggest the changes we observed in HRV are attributable
to factors other than physical activity level (Tsai et al., 2011).
The increased HR observed in sensitized animals, which is con-
sistent with high resting HR in asthmatic patients, could be due
to increased cardiac SNS tone, higher levels of circulating cate-
cholamines, withdrawal of PSNS tone, or some combination of
the aforementioned (Lewis et al., 2006). Further studies charac-
terizing the nature and time-course of HRV changes in asthma
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disease progression or in animalmodels of asthma, are required to
elucidate the physiologic and molecular mechanisms responsible.
In summary, to our knowledge this is the first study to
document the use of chronic instrumentation and ANS assess-
ment via HRV in allergically sensitized mice before, during and
after aerosol challenge at early disease onset. Chronic instru-
mentation with radiotelemetry devices provides a robust way
of gathering integrative physiological data to monitor the ANS
phenotype of allergic sensitization. In the presence of mild sen-
sitization, as evidenced by AHR, sensitized mice exhibit sig-
nificant changes in HRV during acclimation, aerosol exposure
and for the 22 h following aerosol challenge. Most strikingly,
HRV is depressed in sensitized mice prior to Ag challenge, and
exhibits a prolonged reduction in almost all indices for 10 h
after aerosol exposure (i.e., during the dark/active cycle of the
mice). This suggests that sensitization independently impacts
on ANS activity, as measured through HRV analysis. Further
studies are required to elucidate the integrative impact of sen-
sitization, and the putative mechanisms responsible for these
alterations.
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